Safety Comparison of Foscarnet and Ganciclovir in the Treatment of Cytomegalovirus Infection with AIDS

doi:10.19803/j.1672-8629.2021.01.07

Abstract

Abstract: Objective To compare the safety of foscarnet and ganciclovir in the treatment of cytomegalovirus in patients with AIDS so as to provide reference for safe and rational use of drugs.Methods A total of 315 cytomegalovirus infection patients with AIDS treated with foscarnet or ganciclovir between January 2018 and January 2019 were collected,who were divided into the foscarnet group(n=155) and the ganciclovir group(n=160).Safety was evaluated after treatment.Results Foscarnet could induce regional numbness,twitch and abnormalities of electrolytes,while ganciclovir often led to myelosuppression and gastrointestinal reactions.The incidence of adverse reactions (ADR) in the foscarnet group(45.155) was statistically lower than in the ganciclovir group(72.50%).The withdrawal rate of foscarnet due to ADRs was 44.28%,compared with 64.66% for ganciclovir.The ganciclovir group was more likely to switch to an alternative treatment.After withdrawal of foscarnet or ganciclovir and symptomatic treatment,most of the symptoms disappeared and no serious sequelae or death occurred.Conclusion Foscarnet is safer than ganciclovir.According to the clinical manifestations of adverse reactions caused by foscarnet or ganciclovir,drugs that are likely to cause the same adverse reactions as the drugs being used should not be used to reduce the superposition of adverse reactions when AIDS patients are CMV infected.The incidence of ADRs,the withdrawal rate of foscarnet due to ADRs and the proportion of cases of switch to an alternative treatment in the foscarnet group are all lower than in the ganciclovir group,so foscarnet can be considered once ganciclovir is not tolerated.

Key words: AIDS, cytomegalovirus infection, foscarnet, ganciclovir, safety evaluation

CLC Number:

R994.11

XUE Xiaola, XIA Yuchao, LI Chaofeng, CHEN Yuanyuan. Safety Comparison of Foscarnet and Ganciclovir in the Treatment of Cytomegalovirus Infection with AIDS[J]. Chinese Journal of Pharmacovigilance, 2021, 18(1): 38-42.

References

[1] Osuri S,Muhammad R,Ruiz J,et al.Acute necrotizing pancreatitis in the setting of CMV viremia and AIDS:a case report and review of literature from 1980 to 2012[J].JOP,2012,12(6):705-711.
[2] LI TS,Wang FS,Gao F.Chinese guidelines for diagnosis and treatment of HIV/AIDS (2018)[J].Medical Journal of Peking Union Medical College Hospital(协和医学杂志),2018,10(1):41-63 .
[3] Mehta U,Durrheim DN,Blockman M,et al.Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence:prospective observational study[J].Br J Clin Pharmacol,2007,65(3):396-406.
[4] Wang P,Peng H,Lou FD,et al.2 cases of hypocalcemia and hypokalemia induced by foscarnet[J].Chin Hospi Pharm J(中国医院药学杂志),2001,21(1):62.
[5] Chen KJ,Li XL,Zhang Y CH.1 case of limbs anesthesia induced by foscarnet[J].Chin J Pharmacoepidemiol(药物流行病学杂志),2017,26(2):149-150.
[6] Xue XL,Chen YY.Foscarnet-induced adverse drug reactions in patients with acquired immunodeficiency syndrome[J].Central South Pharmacy,2018,16(12):1803-1807.
[7] Ren XL,Huang J,Li YZH.Foscarnet sodium-related epileptic seizures and renal damage[J].ADRJ(药物不良反应杂志),2010,144(12):239-245.
[8] Hu Y,Liu Y,Liu S,et al.Analysis of foscarnet-induced adverse drug reaction in Beijing area from 2008 to 2014[J].Chin Pharm J(中国药学杂志),2015,18(50):1634-1638.
[9] Brett P,Lisa L,Anne A,et al.Safety and efficacy of foscarnet for the management of ganciclovir‐resistant or refractory cytomegalovirus infections:A single‐center study[J].Transpl Infect Dis,2018,20(2):e12852.
[10] Guan X,Chen SX,Xu LM,et al.Efficacy and safety of foscarnet sodium in the treatment of 112 cases of herpes zoster[J].Chin J Derm Venereol(中国皮肤性病学杂志),2014,12(28):1238-1240.
[11] Li DD,Xie Q,Wang Y,et al.Acute renal failure associated with foscarnet sodium[J].ADRJ(药物不良反应杂志),2012,14(5):317-319.
[12] Hao SL,Xu HM.A study on adverse effects of ganciclovir in 111 infants with cytomegalovirus infection[J].Chin J Evid Based Pediatr(中国循证儿科杂志),2016,11(6):431-435.
[13] Li WY.Clinical analysis of ganciclovir in treatment of 90 cases with congenital cytomegalovirus infection[J].Journal of Clinical Medical Literature(临床医药文献杂志),2019,6(9):155-158.
[14] Wu NN,Ge LH,Du H,et al.Analysis on adverse drug reaction of HIV/AIDS patient in Nanning city[J].Chin J of Clinical Rational Drug Use(临床合理用药),2012,1A(5):11-12.
[15] Wang F,Gao GJ,Sun N,et al.Analysis of adverse drug reactions in 95 AIDS patients[J].Clinical Medication Journal(临床药物治疗杂志),2013,6(11):20-24.
[16] Liu Y,Xiang SN,Tang P.One case of extrapyramidal reaction induced by ganciclovir injection[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2016,13(2):120-122.
[17] Choi WS,Koh JW,Chung TY,et al.Cytotoxicity of ganciclovir on cultured human corneal endothelial cells[J].Antivir Ther,2013,18(6):813-820.
[18] Du H,Zhao LH,Qin ZY,et al.Effects of myelosuppression in HIV/AIDS patients on death during HARRT treatment[J].China Pharmacy(中国药房杂志),2015,26(35):4951-4954.
[19] He Q,Kong SY,Xu C,et al.The Efficacy and safety of foscarnet versus ganciclovir for cytomegalovirus retinitis associated with AIDS[J].Chin J Evid-based Med(中国循证医学杂志),2006,6(7):507-513.
[20] Richard AL,Pamela C,Victor C,et al.Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial[J].Arch Intern Med,1995,155(1):65-74.